Drug Trial Radar · NCT06513104
A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause
Last checked: Nov 20, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
47
Actual
Start
Jul 18, 2024
Primary completion
Sep 10, 2025
Study completion Sep 30, 2025
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jul 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to investigate if NNC0519-0130 affects the blood levels of a birth control pill that contains the two hormones ethinylestradiol and levonorgestrel. The study will also look into if NNC0519-0130 affects how fast stomach is emptied. Participants will get the new study medicine NNC0519-0130 and will also get birth control pills and paracetamol. The study will last for about 35 weeks.
Conditions
- Diabetes Mellitus, Type 2
Interventions
NNC0519-0130Drug
NNC0519-0130 will be administered subcutaneously.
Levonorgestrel + EthinylestradiolDrug
Levonorgestrel + Ethinylestradiol will be administered orally.
ParacetamolDrug
Paracetamol will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the ethinylestradiol plasma concentration time curve during a dosing interval at steady stateTime frame: Day 8
- Area under the ethinylestradiol plasma concentration time curve during a dosing interval at steady stateTime frame: Day 188
- Area under the levonorgestrel plasma concentration time curve during a dosing interval at steady stateTime frame: Day 8
- Area under the levonorgestrel plasma concentration time curveduring a dosing interval at steady stateTime frame: Day 188
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Parexel International GmbH
Berlin, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.